Dezerv

Fund Overview

Fund Size

Fund Size

₹162 Cr

Expense Ratio

Expense Ratio

0.43%

ISIN

ISIN

INF00XX01BO9

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

11 Nov 2021

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ITI Mutual Fund. This fund has been in existence for 2 years, 6 months and 7 days, having been launched on 11-Nov-21.
As of 17-May-24, it has a Net Asset Value (NAV) of ₹14.32, Assets Under Management (AUM) of 161.86 Crores, and an expense ratio of 0.43%.
  • ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 15.33% since inception.
  • The fund's asset allocation comprises around 99.68% in equities, 0.00% in debts, and 0.32% in cash & cash equivalents.
  • You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+48.44%

+50.98% (Cat Avg.)

Since Inception

+15.33%

(Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity161.35 Cr99.68%
Others0.52 Cr0.32%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity25.58 Cr15.81%
Max Healthcare Institute Ltd Ordinary SharesEquity9.96 Cr6.15%
Lupin LtdEquity9.8 Cr6.05%
Dr Reddy's Laboratories LtdEquity8.7 Cr5.37%
Mankind Pharma LtdEquity8.19 Cr5.06%
Apollo Hospitals Enterprise LtdEquity7.7 Cr4.75%
Suven Pharmaceuticals LtdEquity7.13 Cr4.41%
Divi's Laboratories LtdEquity6.69 Cr4.14%
Zydus Lifesciences LtdEquity5.86 Cr3.62%
Laurus Labs LtdEquity4.74 Cr2.93%
Cipla LtdEquity3.91 Cr2.41%
Syngene International LtdEquity3.9 Cr2.41%
Torrent Pharmaceuticals LtdEquity3.62 Cr2.23%
J.B. Chemicals & Pharmaceuticals LtdEquity3.57 Cr2.21%
Alembic Pharmaceuticals LtdEquity3.27 Cr2.02%
FDC LtdEquity3.17 Cr1.96%
Ipca Laboratories LtdEquity3.07 Cr1.89%
Piramal Pharma LtdEquity2.98 Cr1.84%
HealthCare Global Enterprises LtdEquity2.92 Cr1.80%
Orchid Pharma LtdEquity2.65 Cr1.63%
Archean Chemical Industries LtdEquity2.47 Cr1.53%
Vijaya Diagnostic Centre LtdEquity2.45 Cr1.51%
Ajanta Pharma LtdEquity2.02 Cr1.25%
Caplin Point Laboratories LtdEquity2 Cr1.24%
Jupiter Life Line Hospitals LtdEquity1.99 Cr1.23%
Aurobindo Pharma LtdEquity1.87 Cr1.16%
Rainbow Childrens Medicare LtdEquity1.76 Cr1.09%
GlaxoSmithKline Pharmaceuticals LtdEquity1.71 Cr1.05%
Sanofi India LtdEquity1.63 Cr1.00%
Vishnu Chemicals LtdEquity1.61 Cr1.00%
Fortis Healthcare LtdEquity1.58 Cr0.97%
Metropolis Healthcare LtdEquity1.56 Cr0.97%
Abbott India LtdEquity1.55 Cr0.96%
Sequent Scientific LtdEquity1.54 Cr0.95%
Astec Lifesciences LimitedEquity1.51 Cr0.93%
Shilpa Medicare LtdEquity1.49 Cr0.92%
Gland Pharma LtdEquity1.37 Cr0.85%
Strides Pharma Science LtdEquity1.33 Cr0.82%
Sumitomo Chemical India Ltd Ordinary SharesEquity1.28 Cr0.79%
Sun Pharma Advanced Research Co LtdEquity1.24 Cr0.76%
Net Receivables / (Payables)Cash0.52 Cr0.32%

Allocation By Market Cap (Equity)

Large Cap Stocks

39.78%

Mid Cap Stocks

30.07%

Small Cap Stocks

28.91%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare154.47 Cr95.43%
Basic Materials5.36 Cr3.31%

Risk & Performance Ratios

Standard Deviation

This fund

--

Cat. avg.

14.57%

Lower the better

Sharpe Ratio

This fund

--

Cat. avg.

0.69

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.16

Higher the better

Fund Managers

Dhimant Shah

Dhimant Shah

Since December 2022

Rohan Korde

Rohan Korde

Since November 2021

Additional Scheme Detailsas of 30th April 2024

ISININF00XX01BO9Expense Ratio0.43%Exit Load1.00%Fund Size₹162 CrAge11 Nov 2021Lumpsum Minimum₹5,000Fund StatusOpen Ended Investment CompanyBenchmarkNifty Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹13.07 Cr54.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.0%1.0%₹694.50 Cr57.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹694.50 Cr55.3%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹36.50 Cr52.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹161.86 Cr48.4%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹161.86 Cr45.4%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2236.01 Cr52.1%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2236.01 Cr49.9%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹639.49 Cr53.9%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹16.41 Cr51.7%

About the AMC

Total AUM

₹6,817 Cr

Address

Mumbai, 400013

Other Funds by ITI Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
ITI Focused Equity Fund Direct Growth

Very High Risk

0.4%1.0%₹374.57 Cr-
ITI Liquid Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹38.22 Cr7.0%
ITI Ultra Short Duration Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹158.44 Cr7.4%
ITI Multi Cap Fund Direct Growth

Very High Risk

0.5%1.0%₹1122.52 Cr56.9%
ITI Value Fund Direct Growth

Very High Risk

0.5%1.0%₹218.04 Cr53.6%
ITI Conservative Hybrid Fund Direct Growth

Moderate Risk

0.2%0.0%₹14.80 Cr8.9%
ITI Dynamic Bond Fund Direct Growth

Moderate Risk

0.1%0.0%₹36.88 Cr7.6%
ITI Balanced Advantage Fund Direct Growth

Very High Risk

0.6%1.0%₹353.06 Cr26.7%
ITI Small Cap Fund Direct Growth

Very High Risk

0.2%1.0%₹1937.79 Cr70.1%
ITI Large Cap Fund Direct Growth

Very High Risk

0.5%1.0%₹296.94 Cr40.7%
ITI Banking & PSU Debt Fund Direct Growth

Moderate Risk

0.1%0.0%₹30.05 Cr7.3%
ITI Banking and Financial Services Fund Direct Growth

Very High Risk

0.4%1.0%₹267.94 Cr18.8%
ITI Arbitrage Fund Direct Growth

Low Risk

0.2%0.0%₹26.27 Cr8.4%
ITI Overnight Fund Direct Growth

Low Risk

0.1%0.0%₹211.77 Cr6.6%
ITI Mid Cap Fund Direct Growth

Very High Risk

0.4%1.0%₹820.00 Cr72.3%
ITI Long Term Equity Fund Direct Growth

Very High Risk

0.5%0.0%₹325.14 Cr58.0%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹161.86 Cr48.4%
ITI Flexi Cap Fund Direct Growth

Very High Risk

0.4%1.0%₹937.99 Cr52.7%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of ITI Pharma and Healthcare Fund Direct Growth, as of 17-May-2024, is ₹14.32.
The fund's allocation of assets is distributed as 99.68% in equities, 0.00% in bonds, and 0.32% in cash and cash equivalents.
The fund managers responsible for ITI Pharma and Healthcare Fund Direct Growth are:-
  1. Dhimant Shah
  2. Rohan Korde